Kymera Therapeutics' Founder & CEO Nello Mainolfi recaps Monday's STAT6 data and discusses the next steps in development
He talks about Kymera's dosing methodology, and recaps the data from a degredation, biomarker, and clinical outcomes standpoint. Plus, next steps in STAT6, and thoughts on the platform in general and the field more broadly.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.